#United States #Washington, DC #Novo Nordisk #CagriSema #ObesityWeek

Novo's CagriSema Demonstrates Effective Weight Loss in Latest Trial Results

At the recent ObesityWeek® 2026 held in Washington, DC, Novo Nordisk unveiled significant findings from a post hoc analysis of their phase 3 trial, REDEFINE 1, focusing on the investigational drug CagriSema. This novel medication, which combines the long-acting amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, was explored for its impacts on weight loss and overall physical function in adults suffering from overweight or obesity.

The analysis revealed an impressive 67.8% of participants on CagriSema 2.4 mg / 2.4 mg status as early responders, indicating they achieved at least 5% weight loss by week 8. Following up on this promising start, early responders exhibited a mean weight loss of about 25.4% by the 68th week compared to 17.8% among delayed responders. Notably, women showed a higher early response with 71.8% versus 59.5% of men, indicating a potential variance in treatment efficacy across genders.

The data from REDEFINE 1 underscores a critical aspect of obesity treatment. Martin Holst Lange, EVP and chief scientific officer at Novo Nordisk, stated, “Obesity is a chronic disease, and people respond to treatment differently and over different timeframes.